Skip to content
  • News & Events
    • Press & Media
  • Culture
    • Careers
  • Partnering
  • Investors
  • Contact
Menu
  • News & Events
    • Press & Media
  • Culture
    • Careers
  • Partnering
  • Investors
  • Contact
  • Science
    • Barriers to Treatment in the Liver
    • Barriers to Treatment in the Pancreas
    • Overcoming Immunosuppression
    • Overcoming Intratumoral Pressure
    • Publications & Presentations
  • Platform
    • Drug Delivery Technology
  • Pipeline
    • Candidate SD-101
  • Clinical Trials
  • For Patients
  • About
Menu
  • Science
    • Barriers to Treatment in the Liver
    • Barriers to Treatment in the Pancreas
    • Overcoming Immunosuppression
    • Overcoming Intratumoral Pressure
    • Publications & Presentations
  • Platform
    • Drug Delivery Technology
  • Pipeline
    • Candidate SD-101
  • Clinical Trials
  • For Patients
  • About
Menu
  • Science
    • Barriers to Treatment in the Liver
    • Barriers to Treatment in the Pancreas
    • Overcoming Immunosuppression
    • Overcoming Intratumoral Pressure
    • Publications & Presentations
  • Platform
    • Drug Delivery Technology
  • Pipeline
    • Candidate SD-101
  • Clinical Trials
  • For Patients
  • About
  • News & Events
    • Press & Media
  • Culture
    • Careers
  • Partnering
  • Investors
  • Contact
  • OUR TEAM

Anil Singhal

  • Director

Dr. Anil Singhal is currently the President and Chief Executive Officer of Trishula Therapeutics, a privately held, clinical-stage company developing TTX-030, a CD39 antibody in multiple solid tumors. Previously, he held a similar role at Adicet Bio, a company developing allogeneic cell therapy in cancer.  He joined Adicet from Canaan Partners where he served as Executive in Residence and OncoResponse Inc., where he served as Chief Scientific Officer. He is the former Vice President of Early Oncology Development of AbbVie and Head of its Abbvie-Redwood City, California site. During his tenure at AbbVie, Anil oversaw the global regulatory approval of Empliciti in multiple myeloma and Daclizumab in multiple sclerosis. As a member of the R&D leadership team, he helped to guide an impressive portfolio and key translational science capabilities in oncology and other diseases.

Anil has held senior roles in the U.S., Japanese and German biopharma/biotechnology industry leading to the approvals of Prosorba in auto-immune disease and talaporfin sodium in non-small cell lung cancer. Prior to his industry tenure, he was Assistant Research Professor at Mount Sinai School of Medicine and concurrent with the industry role, Adjunct Associate Professor at the University of Washington.

© 2023 TriSalus Life Sciences, Inc. All rights reserved
  • Privacy Policy
  • Compliance
  • Terms of Use
Linkedin Twitter
Linkedin Twitter
© 2023 TriSalus Life Sciences, Inc.
All rights reserved
  • Privacy Policy
  • Compliance
  • Terms of Use

IMPORTANT NOTICE

You are now leaving the Trisalus life Sciences corporate website.

We encourage you to read and evaluate terms of use, privacy, security and other similar policies of the destination site as they may differ from TriSalus’ standards.

Third Party Sites

TriSalus assumes no responsibility nor does it control, endorse or guarantee any aspect of your use of any third party sites. Additionally, the presence of this link does not imply the third party site’s endorsement of TriSalus or this website.

Thank you for visiting our site.

YES
CANCEL